You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 7,504,095


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,504,095 protect, and when does it expire?

Patent 7,504,095 protects NULIBRY and is included in one NDA.

This patent has ten patent family members in ten countries.

Summary for Patent: 7,504,095
Title:Method for obtaining precursor Z and use thereof for the production of a means for therapy of human molybdenum cofactor deficiency
Abstract: The invention relates to a method for obtaining the molybdopterin derivative precursor Z, wherein an over-production of precursor Z occurs in host organisms by recombinant expression of precursor Z synthesizing proteins. The invention further relates to the use of precursor Z for the production of a means for the therapy of human molybdenum cofactor deficiency and associated diseases, which may be directly or indirectly attributed to an altered molybdenum cofactor synthesis, whereby precursor Z is used as essential component of said therapy means.
Inventor(s): Schwarz; Guenter (Niederkassel, DE), Mendel; Ralf (Leitferde, DE), Santamaria; Jose (Koln, DE), Reiss; Jochen (Niemetal, DE)
Assignee: Technische Universitaet Braunschweig (Braunschweig, DE)
Application Number:11/343,489
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 7,504,095

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sentynl Theraps Inc NULIBRY fosdenopterin hydrobromide POWDER;INTRAVENOUS 214018-001 Feb 26, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,504,095

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2004 004 642Jan 29, 2004
Germany10 2004 063 948Jan 30, 2004

International Family Members for US Patent 7,504,095

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2554461 ⤷  Sign Up
Cyprus 1113960 ⤷  Sign Up
Germany 102004004642 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.